Nanoparticles activated by ultra-low-energy X-rays effectively halt the aggregation and toxicity of amyloid beta in preclinical models
Bar-Ilan UniversityA collaborative effort between Israeli and Italian researchers has led to the development of a new treatment strategy targeting the early-stage aggregation of A-beta before the formation of toxic oligomers. By harnessing the power of nanotechnology and ultra-low-energy X-rays, the researchers have successfully inhibited the aggregation and toxicity of A-beta in preclinical models, offering a potential avenue for early intervention in Alzheimer’s disease.